ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC).
dc.contributor.author | Coleman, R | |
dc.contributor.author | Oza, A | |
dc.contributor.author | Lorusso, D | |
dc.contributor.author | Aghajanian, C | |
dc.contributor.author | Oaknin, A | |
dc.contributor.author | Dean, A | |
dc.contributor.author | Colombo, N | |
dc.contributor.author | Weberpals, J | |
dc.contributor.author | Clamp, Andrew R | |
dc.contributor.author | Scambia, G | |
dc.contributor.author | Leary, A | |
dc.contributor.author | Holloway, R | |
dc.contributor.author | O’Malley, D | |
dc.contributor.author | Cameron, T | |
dc.contributor.author | Maloney, L | |
dc.contributor.author | Goble, S | |
dc.contributor.author | Lin, K | |
dc.contributor.author | Sun, J | |
dc.contributor.author | Giordano, H | |
dc.contributor.author | Ledermann, J | |
dc.date.accessioned | 2018-10-15T16:46:05Z | |
dc.date.available | 2018-10-15T16:46:05Z | |
dc.date.issued | 2018-08-01 | |
dc.identifier.citation | ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). 2018, 24(15_Suppl): 30-31 Clin Cancer Res | en |
dc.identifier.doi | 10.1158/1557-3265.OVCA17-PR06 | |
dc.identifier.uri | http://hdl.handle.net/10541/621270 | |
dc.language.iso | en | en |
dc.relation.url | http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1557-3265.OVCA17-PR06 | en |
dc.title | ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | The University of Texas MD Anderson Cancer Center, Houston | en |
dc.identifier.journal | Clinical Cancer Research | en |